Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases in the United States. Its lead product candidate is YUTREPIA, an inhaled dry powder formulation of treprostinil for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets Remodulin, a treprostinil injection for continuous intravenous or subcutaneous infusion. Additionally, Liquidia is developing L606, an investigational liposomal formulation of treprostinil currently in Phase III clinical trials for PAH and PH-ILD. The company leverages its proprietary PRINT technology to engineer uniform drug particles with precise control over size, shape, and chemical composition.

Liquidia Corporation is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol LQDA. The company's financial reporting and stock trading are conducted in US Dollars (USD), as it is based in the United States. The NasdaqCM is a US-based exchange that primarily lists smaller-capitalization companies, and Liquidia's listing there provides investors with access to its shares in the US equity market.

Liquidia Corporation operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification indicates that the company is involved in the development and production of specialized pharmaceutical products, including both branded specialty drugs and generic medications. As a biopharmaceutical company, Liquidia focuses on niche therapeutic areas such as rare cardiopulmonary diseases, which aligns with the specialty drug manufacturing segment. The company's pipeline includes both proprietary formulations and licensed technologies, reflecting its role in the broader pharmaceutical manufacturing landscape.

Liquidia Corporation is headquartered in Morrisville, North Carolina, United States. The company primarily serves the US market, as indicated by its focus on the development and commercialization of products for rare cardiopulmonary diseases within the country. While its operations are US-centric, Liquidia has established license and promotion agreements with international partners, such as Pharmosa Biopharm Inc for L606, and collaborations with entities like Vectura, the University of North Carolina at Chapel Hill, GlaxoSmithKline, Alcon Inc, and Sandoz. These partnerships may extend its reach, but its core market remains the United States.

Liquidia Corporation generates revenue primarily through the commercialization of its approved products and the advancement of its pipeline candidates. The company markets Remodulin, a treprostinil injection for PAH and PH-ILD, which provides a steady revenue stream. Additionally, it is developing YUTREPIA and L606, which are expected to contribute future revenue upon approval. Liquidia also leverages its proprietary PRINT technology for drug particle engineering, potentially generating licensing or partnership income. The company has a promotion agreement with Sandoz and license agreements with Pharmosa Biopharm Inc and others, which may include milestone payments and royalties. Overall, its business model centers on developing and selling specialty pharmaceuticals for rare cardiopulmonary conditions.